Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Liquidia Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its focus on innovative therapies for respiratory and vascular diseases [1]. Group 1: Company Overview - Liquidia Corporation is a biopharmaceutical company dedicated to revolutionizing care for patients with challenging respiratory and vascular diseases through innovative therapies and its proprietary PRINTTechnology [3]. - The company’s first approved product is YUTREPIA™ (treprostinil) inhalation powder, which is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3]. - Liquidia is also developing L606, an investigational extended-release formulation of treprostinil, which is administered twice daily using a next-generation nebulizer [3]. - Additionally, the company markets generic Treprostinil Injection for the treatment of PAH [3]. Group 2: Event Information - Dr. Roger Jeffs, the CEO of Liquidia, will present at the conference starting at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) [1]. - A live, audio-only webcast of the presentation will be available on the "Investors" page of Liquidia's website and will be archived for at least 30 days [2].